(Reuters) -Eli Lilly ( LLY ) is in advanced talks to acquire gene editing startup Verve Therapeutics ( VERV ) for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Reuters could not immediately verify the report.